MX381102B - Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. - Google Patents

Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.

Info

Publication number
MX381102B
MX381102B MX2016001384A MX2016001384A MX381102B MX 381102 B MX381102 B MX 381102B MX 2016001384 A MX2016001384 A MX 2016001384A MX 2016001384 A MX2016001384 A MX 2016001384A MX 381102 B MX381102 B MX 381102B
Authority
MX
Mexico
Prior art keywords
benralizumab
asthma
treatment
expiratory volume
forced expiratory
Prior art date
Application number
MX2016001384A
Other languages
English (en)
Other versions
MX2016001384A (es
Inventor
Bing Wang
Christine Ward
Donald Raible
Lorin Roskos
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2016001384A publication Critical patent/MX2016001384A/es
Publication of MX381102B publication Critical patent/MX381102B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)

Abstract

La presente invención se refiere a una cantidad efectiva de benralizumab para usarse en un método para tratar asma al aumentar un volumen espiratorio forzado en un segundo (FEV1) en un paciente asmático, en donde la administración aumenta el FEV1 del paciente, en donde el benralizumab está adaptado para ser administrable a una dosis de 30 mg una vez cada cuatro semanas durante doce semanas y después una vez cada ocho semanas.
MX2016001384A 2013-08-12 2014-08-07 Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. MX381102B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361864948P 2013-08-12 2013-08-12
PCT/US2014/050119 WO2015023507A2 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab

Publications (2)

Publication Number Publication Date
MX2016001384A MX2016001384A (es) 2016-08-03
MX381102B true MX381102B (es) 2025-03-12

Family

ID=52448838

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016001384A MX381102B (es) 2013-08-12 2014-08-07 Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.
MX2021003826A MX2021003826A (es) 2013-08-12 2016-01-29 Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021003826A MX2021003826A (es) 2013-08-12 2016-01-29 Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.

Country Status (26)

Country Link
US (1) US9441046B2 (es)
EP (5) EP3033104B1 (es)
JP (4) JP6746496B2 (es)
KR (1) KR102337599B1 (es)
CN (2) CN105451769A (es)
AU (2) AU2014306959B2 (es)
BR (1) BR112016002317A8 (es)
CA (1) CA2917603C (es)
CY (2) CY1122033T1 (es)
DK (2) DK3033104T3 (es)
ES (2) ES2733602T3 (es)
HK (1) HK1222559A1 (es)
HR (2) HRP20190920T1 (es)
HU (2) HUE043497T2 (es)
LT (2) LT3033104T (es)
ME (1) ME03403B (es)
MX (2) MX381102B (es)
PL (2) PL3033104T3 (es)
PT (2) PT3033104T (es)
RS (2) RS58711B1 (es)
RU (1) RU2703568C2 (es)
SG (1) SG11201600483QA (es)
SI (2) SI3520811T1 (es)
SM (2) SMT202100152T1 (es)
TR (1) TR201907907T4 (es)
WO (1) WO2015023507A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015023504A1 (en) * 2013-08-12 2015-02-19 Medlmmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
EP3033103B1 (en) * 2013-08-12 2019-06-05 AstraZeneca AB Methods for improving asthma symptoms using benralizumab
CN105636607A (zh) * 2013-10-15 2016-06-01 免疫医疗有限责任公司 用于使用贝那利珠单抗治疗慢性阻塞性肺疾病的方法
PT3060229T (pt) * 2013-10-24 2021-10-07 Astrazeneca Ab Formulações aquosas estáveis de anticorpos
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
TW202126688A (zh) * 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法
WO2026053166A1 (en) * 2024-09-06 2026-03-12 Medimmune Limited Anti-il5r-alpha treatment for acute exacerbations of asthma and copd

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010354A1 (fr) 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. Anticorps de la chaine alpha du recepteur de l'interleukine 5 humaine
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2402477A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005035583A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Ｉｌ－５受容体に特異的に結合する抗体組成物
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
HUE026728T2 (en) 2007-05-14 2016-06-28 Medimmune Llc A method for reducing eosinophil levels
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
JP6005657B2 (ja) * 2010-12-16 2016-10-12 ジェネンテック， インコーポレイテッド Ｔｈ２阻害に関連する診断及び治療
CN102544908B (zh) 2010-12-17 2016-01-06 富士康(昆山)电脑接插件有限公司 电连接器组件及插头连接器
WO2012158954A1 (en) * 2011-05-18 2012-11-22 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
KR20140097217A (ko) * 2011-11-01 2014-08-06 메디뮨 엘엘씨 급성 천식 악화의 빈도 및 중증도를 감소시키는 방법
WO2015023504A1 (en) * 2013-08-12 2015-02-19 Medlmmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
EP3033103B1 (en) * 2013-08-12 2019-06-05 AstraZeneca AB Methods for improving asthma symptoms using benralizumab

Also Published As

Publication number Publication date
CA2917603C (en) 2023-05-16
RS61565B1 (sr) 2021-04-29
BR112016002317A8 (pt) 2018-06-12
CA2917603A1 (en) 2015-02-19
ME03403B (me) 2020-01-20
RU2016108809A3 (es) 2018-06-18
HUE043497T2 (hu) 2019-08-28
HK1222559A1 (zh) 2017-07-07
US9441046B2 (en) 2016-09-13
EP4579236A3 (en) 2025-09-17
MX2021003826A (es) 2021-05-27
EP3520811B1 (en) 2020-12-30
HUE053627T2 (hu) 2021-07-28
JP2016527325A (ja) 2016-09-08
SMT201900311T1 (it) 2019-07-11
RS58711B1 (sr) 2019-06-28
PL3520811T3 (pl) 2021-08-02
JP2022120010A (ja) 2022-08-17
SI3033104T1 (sl) 2019-06-28
WO2015023507A8 (en) 2015-09-24
ES2866426T3 (es) 2021-10-19
AU2014306959B2 (en) 2019-11-21
LT3520811T (lt) 2021-03-25
JP6746496B2 (ja) 2020-08-26
TR201907907T4 (tr) 2019-06-21
EP3033104B1 (en) 2019-04-03
DK3033104T3 (da) 2019-06-17
EP3033104A4 (en) 2017-03-22
PT3520811T (pt) 2021-03-15
PL3033104T3 (pl) 2019-09-30
EP4579236A2 (en) 2025-07-02
HRP20190920T1 (hr) 2019-07-12
RU2016108809A (ru) 2017-09-18
MX2016001384A (es) 2016-08-03
SI3520811T1 (sl) 2021-04-30
WO2015023507A2 (en) 2015-02-19
RU2703568C2 (ru) 2019-10-21
AU2020201277A1 (en) 2020-03-12
HRP20210406T1 (hr) 2021-04-30
HK1225300A1 (en) 2017-09-08
EP3520811A1 (en) 2019-08-07
WO2015023507A3 (en) 2015-04-09
EP4636400A2 (en) 2025-10-22
AU2014306959A1 (en) 2016-02-04
EP3875487A1 (en) 2021-09-08
JP2024129140A (ja) 2024-09-26
SG11201600483QA (en) 2016-02-26
EP3033104A2 (en) 2016-06-22
KR102337599B1 (ko) 2021-12-10
PT3033104T (pt) 2019-06-27
SMT202100152T1 (it) 2021-05-07
DK3520811T3 (da) 2021-03-22
CN105451769A (zh) 2016-03-30
US20150044203A1 (en) 2015-02-12
CN111588849A (zh) 2020-08-28
JP2020125304A (ja) 2020-08-20
EP4636400A3 (en) 2025-12-24
KR20160043049A (ko) 2016-04-20
CY1122033T1 (el) 2020-10-14
CY1124399T1 (el) 2022-07-22
ES2733602T3 (es) 2019-12-02
LT3033104T (lt) 2019-06-25
BR112016002317A2 (pt) 2017-12-12

Similar Documents

Publication Publication Date Title
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
MX381102B (es) Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.
CY1117986T1 (el) Ενωσεις αρυλ- ή ετεροαρυλ-υποκατεστημενου βενζολιου
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
CY1116987T1 (el) Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις
PY1337526A (es) Métodos para tratar o prevenir asma administrando un antagonista de IL-4R.
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
BR112015022047A2 (pt) métodos para tratar câncer de bexiga
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201690561A1 (ru) Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i
EA201600434A1 (ru) Применение производных бензимидазолпролина
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
MX376183B (es) Composiciones para el tratamiento de rosacea.
MX2016001195A (es) Metodos para mejorar sintomas de asma mediante el uso de benralizumab.
EA201692518A2 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
EA201500736A1 (ru) Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов
EA201491581A1 (ru) Везикулярные композиции
MX381429B (es) Tricostatina a (tsa) para usarse en el tratamiento del cáncer.
MX386151B (es) Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple.